CMC Icos Biologics said today that it has put a major expansion of its Bothell facility on hold in a bid to save cash amid the economic downturn.
CMC Icos Biologics said today that it has put a major expansion of its Bothell facility on hold in a bid to save cash amid the economic downturn.
“With the current challenges of the global economy, we must carefully manage our resources,” President Gustavo Mahler said in a statement.
The expansion, announced in September and scheduled for completion in 2010, would have nearly doubled the company’s 141-strong workforce and quintupled its capacity to churn out biotechnology compounds on contract. The project was estimated to cost $35 million.
CMC Icos Biologics said it hasn’t set a new completion date yet, and wouldn’t do so in the near term.
Most Read Business Stories
CMC Icos Biologics was formed when Danish company CMC acquired the contract manufacturing unit of Icos a few months after the local biotech success was acquired — and essentially dissolved — by pharmaceutical giant Lilly.
Ángel González: 206-515-5644 or agonzalez@seattletimes.com